Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

111 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cerebellar superficial siderosis (SS) has been recently reported to be present in about 10% of both hereditary (n=50) and sporadic (n=46) cerebral amyloid angiopathy (CAA) patients on 3T MRI using susceptibility-weighted imaging (SWI) in the majority of patients. In that study, cerebellar SS was associated with a higher number of supratentorial lobar and superficial cerebellar macrobleeds (although cerebellar SS was not directly located adjacent to these cerebellar macrobleeds). It is unclear if cerebellar SS is caused by in situ leakage of cerebellar leptomeningeal vessels or rather represents hemorrhagic diffusion from cerebellar parenchymal micro/macrobleeds or from supratentorial bleeding sources via the tentorium cerebelli (TC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.

NCT03464344

Cerebral Amyloid Angiopathy

COMPLETED NA

Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy

NCT01856699

Intracerebral Hemorrhage Cerebral Amyloid Angiopathy Ischemic Stroke

UNKNOWN

Dilated Perivascular Spaces in the Dentate Nucleus on MRI in Patients with Hypertensive Angiopathy or Cerebral Amyloid Angiopathy

NCT06888882

Hypertensive Arteriopathy Cerebral Amyloid Angiopathy

NOT_YET_RECRUITING

High Frequency Imaging in Cerebral Amyloid Angiopathy

NCT06128824

Cerebral Amyloid Angiopathy

ACTIVE_NOT_RECRUITING

Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy

NCT05486897

Cerebral Amyloid Angiopathy Hypertensive Arteriopathy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Amyloid Angiopathy Siderosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cerebral amyloid angiopathy (CAA)

Clinical and 1.5T MRI T2\*-weighted imaging characteristics analyses from sporadic probable CAA patients (according to the modified Boston criteria) presenting with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS,

None, pure observational study

Intervention Type OTHER

None, pure observational study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

None, pure observational study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CAA patients (according to the modified Boston criteria)
* with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS

Exclusion Criteria

* Patients with recent trauma,
* Patients with anticoagulation treatment,
* Patients with pathological blood coagulation tests (activated partial thromboplastin time \[aPTT\] ratio=patient's aPTT/normal control aPTT\] \>1.2; or partial thromboplastin time \[PTT\] \<75%) or platelet count (\<100 x 109/L)
* Patients with inflammatory CAA

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No